Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLUNASDAQ:CRONTSE:CXRTSE:PLI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUBELLUS Health$14.74$14.62$6.38▼$14.76$1.87B0.193.08 million shs3.45 million shsCRONCronos Group$2.05+3.5%$1.82$1.60▼$3.14$790.08M1.061.33 million shs2.92 million shsCXRConcordia InternationalC$0.00C$19.02▼C$417.00C$1.22BN/A4,054 shs73,541 shsPLIProMetic Life SciencesC$0.00C$7.13▼C$590.00C$317.06MN/A8,002 shs921 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUBELLUS Health0.00%0.00%0.00%0.00%0.00%CRONCronos Group0.00%+7.61%+13.14%+1.02%-28.52%CXRConcordia International0.00%0.00%0.00%0.00%0.00%PLIProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUBELLUS HealthN/AN/AN/AN/AN/AN/AN/AN/ACRONCronos Group1.4721 of 5 stars2.04.00.00.02.50.01.3CXRConcordia InternationalN/AN/AN/AN/AN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUBELLUS Health 0.00N/AN/AN/ACRONCronos Group 0.00N/A$3.5070.73% UpsideCXRConcordia International 0.00N/AN/AN/APLIProMetic Life Sciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUBELLUS Health$15K124,613.93N/AN/A$3.09 per share4.77CRONCronos Group$117.62M6.72N/AN/A$2.87 per share0.71CXRConcordia InternationalC$569.62M0.00N/A5.85C$6.08 per share0.00PLIProMetic Life SciencesC$39.91M0.00N/A3.94C$6.07 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUBELLUS Health-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/ACRONCronos Group-$73.96M$0.10N/A68.331.74-42.65%-2.56%-2.47%N/ACXRConcordia InternationalN/AC$351.680.07N/AN/AN/AN/AN/AN/APLIProMetic Life SciencesN/A-C$63.06N/AN/AN/AN/AN/AN/AN/ALatest CRON, CXR, BLU, and PLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUBELLUS HealthN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/ACXRConcordia InternationalN/AN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUBELLUS HealthN/A33.4233.42CRONCronos GroupN/A24.2423.05CXRConcordia International457.022.101.66PLIProMetic Life Sciences37.474.063.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUBELLUS Health90.37%CRONCronos Group8.71%CXRConcordia InternationalN/APLIProMetic Life SciencesN/AInsider OwnershipCompanyInsider OwnershipBLUBELLUS Health24.17%CRONCronos Group7.30%CXRConcordia InternationalN/APLIProMetic Life SciencesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUBELLUS Health74126.81 million96.16 millionNot OptionableCRONCronos Group450385.41 million356.14 millionOptionableCXRConcordia International22,50048.91 millionN/ANot OptionablePLIProMetic Life Sciences48723.31 millionN/ANot OptionableCRON, CXR, BLU, and PLI HeadlinesRecent News About These CompaniesNew PLI Treatise Helps Practitioners Navigate the Complexities of Trade Secret LawOctober 3, 2024 | ipwatchdog.comRethinking rare diseases: treat the whole patientAugust 29, 2024 | pharmaphorum.comPanetta Institute for Public PolicyMarch 31, 2024 | scu.edu2024 Breakthrough Prizes in Life SciencesOctober 11, 2023 | the-scientist.comTMC Life Sciences Bhd (TMCN)July 24, 2023 | investing.comLife Sciences Learning CommunityJune 13, 2023 | slu.eduChicago Life Sciences SummitApril 21, 2023 | bisnow.comCollege of Liberal Arts & SciencesApril 10, 2023 | alfred.eduLabviva nets $20M Series A to ease life science procurement processMarch 27, 2023 | endpts.comTrends that will shape the life sciences industry in 2023 and beyondFebruary 24, 2023 | hindustantimes.comPharma sector gets first tranche of payment under under PLI schemeFebruary 24, 2023 | moneycontrol.comArithmos appoints Maurizio Giraudo as Managing Director of the new Life Sciences Business Consulting UnitFebruary 21, 2023 | finance.yahoo.comWEF, Telangana joins hands to start thematic centre on healthcare and life sciencesJanuary 18, 2023 | health.economictimes.indiatimes.comWorking on PLI schemes for more sectors: Piyush GoyalSeptember 24, 2022 | retail.economictimes.indiatimes.comTSX:CVE (CENOVUS ENERGY INC.)July 31, 2021 | fool.caNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumAST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer StockBy Jea Yu | April 21, 2025View AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer StockHidden Gems: 3 Quiet Stocks With Loud PotentialBy Nathan Reiff | April 23, 2025View Hidden Gems: 3 Quiet Stocks With Loud Potential Microsoft: A Blend of Growth and Value Amid Tariff ConcernsBy Chris Markoch | April 15, 2025View Microsoft: A Blend of Growth and Value Amid Tariff ConcernsCRON, CXR, BLU, and PLI Company DescriptionsBELLUS Health NASDAQ:BLUBELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.Cronos Group NASDAQ:CRON$2.05 +0.07 (+3.54%) Closing price 04:00 PM EasternExtended Trading$2.04 -0.01 (-0.49%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Concordia International TSE:CXRConcordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.ProMetic Life Sciences TSE:PLIPrometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
